||At the Clinic and Policlinic for Cardiac Surgery of Rostock, the treatment with purified patient´s own bone-marrow-derived stem cells is now accepted by the health insurance funds as an innovative therapy. Today this therapy can be applied to patients with the following indications:
- after a myocardial infarction, when a bypass surgery is essential,
- when the pump function of the heart is restricted, as demonstrated by a MRT-test,
- heart insufficience as a consequence of ischemic heart disease, when the precise location of the destroyed myocardium is known.
In 2009 the RTC has started a clinical Phase III study involving three institutions. The aim is to apply the stem cell therapy as a standardised treatment also by further clinics in the future.